Novavax vaccine shows resilient defense against symptomatic

Recent study assesses NVX-CoV2373 vaccine's effectiveness against Omicron variant. Findings show decreased efficacy over four months, but stable protection against symptomatic COVID-19.

Related Keywords

Italy , , National Integrated Surveillance System , Estimated Effectiveness , Primary Cycle , Protein Recombinant Vaccine , National Integrated Surveillance , Coronavirus Disease Covid 19 , Vaccine , Ntigen , Coronavirus , Efficacy , Immunity , Ortality , Micron , Pandemic , Protein , Espiratory , Ibonucleic Acid , Cars , Ars Cov 2 , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Yndrome ,